Summary
Both streptozotocin and chlorozotocin, the 2-chloroethyl analogue of streptozotocin, are diabetogenic chemicals in rodents. Although these chemicals are similar structurally, they appear to act on pancreatic B cells via different mechanisms [1, 2]. In studies here, damage and repair of DNA after exposure of an insulin-secreting cell line to streptozotocin and chlorozotocin were assessed by nucleoid sedimentation and alkaline elution. Equitoxic concentrations of streptozotocin and chlorozotocin caused significant single-strand breakage of DNA (p<0.005). These lesions were repaired in a time-dependent manner, with most repair completed by 24-h post-exposure to chemicals. Additionally, chlorozotocin caused DNA-DNA and DNA-protein crosslinks in insulinoma cells. When proteinase K was included in the crosslinking assay, a substantial proportion of the chlorozotocin-associated crosslinks proved to be DNA interstrand in nature. Analysis of the amount of interstrand crosslinking in insulinoma cells after exposure to chlorozotocin for 1 h showed that formation of interstrand crosslinks was slow. Increasing amounts appeared over a 24-h period. These results suggest that the formation of irreversible DNA interstrand crosslinks may be a critical factor in cytotoxicity and diabetogenicity caused by chlorozotocin.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Mossman BT, Wilson GL, Craighead JE (1985) A diabetogenic analogue of streptozocin with dissimilar mechanisms of action on pancreatic beta cells. Diabetes 34: 602–607
Wilson GL, Mossman BT, Craighead JE (1983) Use of pancreatic B cells in culture to identify diabetogenic N-nitrosos compounds. In Vitro 19: 25–30
Byme PJ, Schein PS (1981) Streptozotocin. In: Prestayko AW, Baker LH, Crooke ST, Carter SK, Schein PS (eds) Nitrosoureas: current status and new developments. Academic, New York, pp, 367–377
Wilson GL, Mossman BT, Craighead JE (1980) Diabetogenic effects of chlorozotocin on murine pancreatic beta cellsin vitro andin vivo. J Cell Biol 87: 327a
Rossini AA, Williams RM, Appel MC, Like AA (1978) Complete protection from low-dose streptozotocin-diabetes in mice. Nature 76: 182–183
Rossini AA, Like AA, Dulin WE, Cahill GF (1977) Pancreatic beta cell toxicity by streptozotocin anomers. Diabetes 26: 1120–1124
Ganda OP, Rossini AA, Like AA (1976) Studies on streptozotocin diabetes. Diabetes 25: 595–603
Anderson T, Schein PS, McMenamin MG, Cooney DA (1974) Streptozotocin diabetes. Correlation with extent of depression of pancreatic islet nicotinamide adenine dinucleotide. J Clin Invest 54: 672–677
Schein PS, Cooney DA, Vernon ML (1976) The use of nicotinamide to modify the toxicity of streptozotocin diabetes without loss of antitumour activity. Cancer Res 27: 2324–2331
Ho CK, Hashim SA (1972) Pyridine nucleotide depletion in pancreatic islets associated with streptozotocin-induced diabetes. Diabetes 21: 789–793
Yamamoto H, Uchigata Y, Okamoto H (1981) Streptozotocin and alloxan induced DNA strand breaks and poly (ADP-ribose) synthetase in pancreatic islets. Nature 294: 284–286
Uchigata Y, Yamamota H, Kawamura A, Okamoto H (1982) Protection by superoxide dismutase, catalase, and poly (ADP-ribose) synthetase inhibitors against alloxan-and streptozotocin-induced islet DNA strand breaks and against the inhibition of proinsulin synthesis. Biol Chem 257: 6024–6088
Uchigata Y, Yamamoto H, Nagia H, Okamoto H (1983) Effect of poly (ADP-ribose) synthetase inhibitor administration to rats before and after injection of alloxan and streptozotocin on islet proinsulin synthesis. Diabetes 32: 316–318
Wheeler GP (1975) In: Sartorelli AC, Johns DG (eds) Handbook of experimental pharmacology, Vol 38, Springer, New York, pp 65–79
Wheeler GP (1975) In: Sartorelli AC (ed) Cancer chemotherapy, Vol 30. American Cancer Society, Washington DC, pp 87–119
Colvin M, Brundrett RB, Cowens W, Jardine I, Ludlum DB (1976) A chemical basis for the antitumour activity of chloroethylnitrosoureas. Biochem Pharmacol 25: 695–699
Reed DJ, May HE, Boose RB, Greagory KM, Beilstein MA (1975) 2-chloroethanol formation as evidence for a 2-chloroethyl alkylating intermediate during chemical degradation of 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea and 1-(2-chlorethyl)-3-(trans4-methylcyclohexyl)-1-lnitrosourea. Cancer Res 35: 568–576
Ewig RAG, Kohn KW (1977) DNA damage and repair in mouse leukaemia LI2I0 cells treated with nitrogen mustard; 1,3-bis(2-chloroethyl)-1-nitrosourea and other nitrosoureas. Cancer Res 37: 2114–2122
Ewig RAG, Kohn KW (1978) DNA protein crosslinking and DNA interstrand crosslinking by haloethyl nitrosoureas in L1210 cells. Cancer Res 38: 3197–3203
LeDoux S, Wilson GL (1984) Effects of streptozotocin on a clonal isolate of rat insulinoma cells. Biochem Biophy Acta 804: 387–392
Ireland CM, Eastman A, Bresnick E (1982) DNA-protein crosslinks induced in a hamster tracheal epithelial cell line by benzo (a) pyrene. Biochem Biophys Res Comm 109(4): 1291–1296
Kohn KW, Erickson LC, Ewig RAG, Friedman CA (1976) Fractionation of DNA from mammalian cells by alkaline elution. Biochemistry 15: 4629–4637
Kohn KW (1979) DNA as target in cancer chemotherapy: Measurements of macromolecular DNA damage produced in mammalian cells by anti-cancer agents and carcinogens. In: DeVita VT, Busch H (eds) Methods in research. Vol 14.Academic, New York, pp 291–345
Gralla RJ, Tan CTC, Young CW (1979) Phase 1 trial of chlorozotocin. Cancer Treat Rep 63: 17–20
Margison GP, Kleihues P (1975) Chemical carcinogenesis in the nervous system: Preferential accumulation of O6-methylguanine in rat brain deoxyribonucleic acid during repetitive administration of N-methyl-N-nitrosourea. Biochem J 148: 521–525
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mossman, B.T., Ireland, C.M., Filipak, M. et al. Comparative interactions of streptozotocin and chlorozotocin with DNA of an insulin-secreting cell line (RINr). Diabetologia 29, 186–191 (1986). https://doi.org/10.1007/BF02427091
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02427091